StockNews.com Initiates Coverage on Aethlon Medical (NASDAQ:AEMD)

Research analysts at StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright dropped their price target on shares of Aethlon Medical from $23.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, March 4th.

Aethlon Medical Stock Performance

Shares of Aethlon Medical stock opened at $1.37 on Friday. The firm has a 50-day simple moving average of $1.64 and a two-hundred day simple moving average of $1.75. Aethlon Medical has a fifty-two week low of $1.33 and a fifty-two week high of $5.00. The company has a market cap of $3.59 million, a P/E ratio of -0.27 and a beta of 1.88.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.14). Equities research analysts forecast that Aethlon Medical will post -4.98 EPS for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.